MA30434B1 - Inhibiteurs d'aldh-2 utilises pour le traitement d'une accoutumance - Google Patents
Inhibiteurs d'aldh-2 utilises pour le traitement d'une accoutumanceInfo
- Publication number
- MA30434B1 MA30434B1 MA31422A MA31422A MA30434B1 MA 30434 B1 MA30434 B1 MA 30434B1 MA 31422 A MA31422 A MA 31422A MA 31422 A MA31422 A MA 31422A MA 30434 B1 MA30434 B1 MA 30434B1
- Authority
- MA
- Morocco
- Prior art keywords
- aldh
- treatment
- inhibitors
- accussion
- derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000003187 aldehyde dehydrogenase inhibitor Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- -1 AMPHETAMINES Chemical compound 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229930012930 isoflavone derivative Natural products 0.000 abstract 1
- 150000002515 isoflavone derivatives Chemical class 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Addiction (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83408306P | 2006-07-27 | 2006-07-27 | |
| US84642806P | 2006-09-21 | 2006-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30434B1 true MA30434B1 (fr) | 2009-05-04 |
Family
ID=38792141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31422A MA30434B1 (fr) | 2006-07-27 | 2008-11-27 | Inhibiteurs d'aldh-2 utilises pour le traitement d'une accoutumance |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080032995A1 (https=) |
| EP (1) | EP2046769A2 (https=) |
| JP (1) | JP2009544742A (https=) |
| KR (1) | KR20090033417A (https=) |
| AU (1) | AU2007278877A1 (https=) |
| CA (1) | CA2653056A1 (https=) |
| CO (1) | CO6210811A2 (https=) |
| EC (1) | ECSP088919A (https=) |
| IL (1) | IL195400A0 (https=) |
| MA (1) | MA30434B1 (https=) |
| MX (1) | MX2008015765A (https=) |
| NO (1) | NO20084971L (https=) |
| RU (1) | RU2008151762A (https=) |
| WO (1) | WO2008014497A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080207610A1 (en) * | 2006-07-27 | 2008-08-28 | Jeff Zablocki | Aldh-2 inhibitors in the treatment of addiction |
| US8158810B2 (en) * | 2006-07-27 | 2012-04-17 | Gilead Sciences, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| KR20090117950A (ko) | 2007-03-08 | 2009-11-16 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법 |
| JP2010523590A (ja) | 2007-04-05 | 2010-07-15 | ギリアード・パロ・アルト・インコーポレイテッド | Ａｌｄｈ−２阻害剤としてのキナゾリノン誘導体 |
| US20090124672A1 (en) * | 2007-11-06 | 2009-05-14 | Ivan Diamond | Aldh-2 inhibitors in the treatment of psychiatric disorders |
| CA2712750A1 (en) * | 2008-01-24 | 2009-07-30 | Gilead Palo Alto, Inc. | Aldh-2 inhibitors in the treatment of addiction |
| CA2713521A1 (en) * | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
| EP2337563B1 (en) | 2008-09-08 | 2014-04-09 | The Board of Trustees of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| KR20110082180A (ko) * | 2008-10-28 | 2011-07-18 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 알데히드 탈수소효소의 조절자 및 그것의 사용방법 |
| JP5819196B2 (ja) * | 2008-10-29 | 2015-11-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 液晶ディスプレイ |
| WO2010118155A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| CA2757622A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| MX361692B (es) | 2010-02-03 | 2018-12-13 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de ácido graso. |
| EP2533638B1 (en) * | 2010-02-12 | 2016-02-10 | Nivalis Therapeutics, Inc. | Novel s-nitrosoglutathione reductase inhibitors |
| WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法 |
| US8933239B1 (en) | 2013-07-16 | 2015-01-13 | Dow Global Technologies Llc | Bis(aryl)acetal compounds |
| US8962779B2 (en) | 2013-07-16 | 2015-02-24 | Dow Global Technologies Llc | Method of forming polyaryl polymers |
| US9063420B2 (en) | 2013-07-16 | 2015-06-23 | Rohm And Haas Electronic Materials Llc | Photoresist composition, coated substrate, and method of forming electronic device |
| US9410016B2 (en) | 2013-07-16 | 2016-08-09 | Dow Global Technologies Llc | Aromatic polyacetals and articles comprising them |
| JP2020536970A (ja) * | 2017-10-16 | 2020-12-17 | アミグダラ ニューロサイエンシス インコーポレイテッド | 嗜癖を予防するための組み合わせ療法 |
| JP7204568B2 (ja) * | 2018-04-04 | 2023-01-16 | 株式会社Cics | アミロイドβ疾患のホウ素中性子捕捉療法用化合物 |
| CN109970738B (zh) * | 2019-02-27 | 2021-07-09 | 上海工程技术大学 | 一种金雀花碱n-异黄酮类化合物及其制备方法及应用 |
| JP2025520426A (ja) | 2022-06-14 | 2025-07-03 | アミグダラ ニューロサイエンシーズ， インコーポレイテッド | Ａｌｄｈ－２阻害化合物及び使用方法 |
| CA3259203A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | ALDH-2 INHIBITING COMPOUNDS AND METHODS OF USE |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3907830A (en) * | 1970-05-27 | 1975-09-23 | Chinoin Gyogyszer Es Vegyeszet | Isoflavone derivatives |
| US4166862A (en) * | 1971-05-25 | 1979-09-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Animal feed containing anabolic isoflavones |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| DE2950135A1 (de) * | 1979-12-13 | 1981-06-19 | Merck Patent Gmbh, 6100 Darmstadt | Basischer aether, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| JPS62201882A (ja) * | 1985-11-18 | 1987-09-05 | Yamanouchi Pharmaceut Co Ltd | イソフラボン誘導体 |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| US5679806A (en) * | 1995-02-24 | 1997-10-21 | Hauser, Inc. | Process for the isolation and purification of isoflavones |
| US5783189A (en) * | 1996-04-23 | 1998-07-21 | Natural Pharmacia International, Inc. | Method for treating alcohol dependence |
| US6255497B1 (en) * | 1997-04-29 | 2001-07-03 | The Endowment For Research In Human Biology, Inc. | Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse |
| CA2334830A1 (en) | 1998-05-12 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| WO2004001058A2 (en) * | 2001-05-04 | 2003-12-31 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| US7368434B2 (en) * | 2002-06-27 | 2008-05-06 | The Endowment For Research In Human Biology, Inc. | Compounds useful for the inhibition of ALDH |
| JP2008504292A (ja) * | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 免疫増強用の化合物 |
| US20080207610A1 (en) * | 2006-07-27 | 2008-08-28 | Jeff Zablocki | Aldh-2 inhibitors in the treatment of addiction |
| US8158810B2 (en) * | 2006-07-27 | 2012-04-17 | Gilead Sciences, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| JP2010523590A (ja) * | 2007-04-05 | 2010-07-15 | ギリアード・パロ・アルト・インコーポレイテッド | Ａｌｄｈ−２阻害剤としてのキナゾリノン誘導体 |
| US20090124672A1 (en) * | 2007-11-06 | 2009-05-14 | Ivan Diamond | Aldh-2 inhibitors in the treatment of psychiatric disorders |
-
2007
- 2007-07-27 EP EP07813501A patent/EP2046769A2/en not_active Withdrawn
- 2007-07-27 CA CA002653056A patent/CA2653056A1/en not_active Abandoned
- 2007-07-27 KR KR1020087029279A patent/KR20090033417A/ko not_active Withdrawn
- 2007-07-27 WO PCT/US2007/074665 patent/WO2008014497A2/en not_active Ceased
- 2007-07-27 AU AU2007278877A patent/AU2007278877A1/en not_active Abandoned
- 2007-07-27 JP JP2009522029A patent/JP2009544742A/ja not_active Withdrawn
- 2007-07-27 MX MX2008015765A patent/MX2008015765A/es not_active Application Discontinuation
- 2007-07-27 US US11/829,836 patent/US20080032995A1/en not_active Abandoned
- 2007-07-27 RU RU2008151762/04A patent/RU2008151762A/ru unknown
-
2008
- 2008-11-20 IL IL195400A patent/IL195400A0/en unknown
- 2008-11-26 NO NO20084971A patent/NO20084971L/no not_active Application Discontinuation
- 2008-11-27 MA MA31422A patent/MA30434B1/fr unknown
- 2008-11-28 EC EC2008008919A patent/ECSP088919A/es unknown
- 2008-12-29 CO CO08137618A patent/CO6210811A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL195400A0 (en) | 2009-08-03 |
| WO2008014497A2 (en) | 2008-01-31 |
| CO6210811A2 (es) | 2010-10-20 |
| AU2007278877A1 (en) | 2008-01-31 |
| NO20084971L (no) | 2009-02-25 |
| ECSP088919A (es) | 2009-01-30 |
| RU2008151762A (ru) | 2010-06-27 |
| MX2008015765A (es) | 2009-03-26 |
| WO2008014497A3 (en) | 2008-04-10 |
| CA2653056A1 (en) | 2008-01-31 |
| US20080032995A1 (en) | 2008-02-07 |
| EP2046769A2 (en) | 2009-04-15 |
| KR20090033417A (ko) | 2009-04-03 |
| JP2009544742A (ja) | 2009-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30434B1 (fr) | Inhibiteurs d'aldh-2 utilises pour le traitement d'une accoutumance | |
| MA32095B1 (fr) | Inhibiteurs d'aldh-2 dans le traitement d'une accoutumance | |
| MA30988B1 (fr) | Composes destines a inhiber la progression mitotique | |
| TN2011000454A1 (fr) | Derives de benzofurannyle utilises comme inhibiteurs de glucokinase | |
| MA35404B1 (fr) | Composés pour le traitement de la toxicomanie | |
| Vougogiannopoulou et al. | One-step semisynthesis of oleacein and the determination as a 5-lipoxygenase inhibitor | |
| Segraves et al. | Investigation of brominated tryptophan alkaloids from two thorectidae sponges: Thorectandra and Smenospongia | |
| TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
| EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
| MA30228B1 (fr) | Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4 | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| MA30526B1 (fr) | Inhibiteurs de prolyle hydroxylase | |
| MA32887B1 (fr) | Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
| MA30358B1 (fr) | Quinazolines pour l'inhibition de pdk1 | |
| TNSN08196A1 (fr) | Derives de pyrazine | |
| MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
| EA201000149A1 (ru) | Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз | |
| MA30427B1 (fr) | Derives bicycliques utilises comme inhibiteurs de cetp | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
| MA27668A1 (fr) | 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire | |
| MA31167B1 (fr) | Inhibiteurs de l'activite de akt | |
| MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
| EP1888066A4 (en) | AMINOCYCLOHEXANE AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer |